Actively Recruiting
Phase 1 Open Label Study of MGC030 for Advanced Solid Tumors Including Dose Escalation, Optimization, and Expansion
Led by MacroGenics · Updated on 2026-10-30
314
Participants Needed
1
Research Sites
25 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating MGC030, an antibody-drug conjugate, in adults with advanced solid tumors that have relapsed or are refractory. The study aims to understand the safety, tolerability, how the drug moves through the body, immune response, and initial anti-tumor activity of MGC030. It focuses on participants with specific solid tumors including urothelial, colorectal, gastric, gastroesophageal, esophageal, and pancreatic cancers. Participants receive MGC030 at escalating dose levels given every three weeks. The study includes dose escalation, dose optimization, and cohort expansion phases to identify the best dose and monitor effects at different levels. Treatments are given under medical supervision, with ongoing assessments throughout the study. During the study, participants undergo screening to confirm eligibility, regular blood tests for routine and research purposes, heart and lung function tests, and general health evaluations. Researchers monitor side effects closely and assess tumor response at regular intervals. The primary focus is on side effects and safety, while secondary measures include drug concentrations, immune responses, tumor response rates, and duration of tumor response, with treatment and follow-up lasting up to two years.
CONDITIONS
Brief Title
A Study of MGC030 in Participants With Advanced Solid Tumors
Research Team
G
Global Trial Manager
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here